Biomimetic nanoparticles: preparation, characterization and biomedical applications.
Mimicking nature is a powerful approach for developing novel lipid-based devices for drug and vaccine delivery. In this review, biomimetic assemblies based on natural or synthetic lipids by themselves or associated to silica, latex or drug particles will be discussed. In water, self-assembly of lipid molecules into supramolecular structures is fairly well understood. However, their self-assembly on a solid surface or at an interface remains poorly understood. In certain cases, hydrophobic drug granules can be dispersed in aqueous solution via lipid adsorption surrounding the drug particles as nanocapsules. In other instances, hydrophobic drug molecules attach as monomers to borders of lipid bilayer fragments providing drug formulations that are effective in vivo at low drug-to-lipid-molar ratio. Cationic biomimetic particles offer suitable interfacial environment for adsorption, presentation and targeting of biomolecules in vivo. Thereby antigens can effectively be presented by tailored biomimetic particles for development of vaccines over a range of defined and controllable particle sizes. Biomolecular recognition between receptor and ligand can be reconstituted by means of receptor immobilization into supported lipidic bilayers allowing isolation and characterization of signal transduction steps.
Carmona-Ribeiro
Ana Maria
AM
Biocolloids Lab, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil. amcr@usp.br
D040761:Biomimetic Materials / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry*
D004337:Drug Carriers
Expert Rev Vaccines. 2003 Apr;2(2):197-203
12899571
J Infect Dis. 1996 Dec;174(6):1168-75
8940205
Nat Biotechnol. 1999 Nov;17(11):1075-81
10545912
Biochemistry. 2007 Feb 27;46(8):2059-69
17263563
Res Immunol. 1992 Jun;143(5):494-503; discussion 574-6
1439129
J Lipid Res. 1997 Oct;38(10):2003-11
9374123
Curr Med Chem. 2006;13(12):1359-70
16719782
J Phys Chem B. 2008 Dec 25;112(51):16422-30
19367939
J Colloid Interface Sci. 2003 Feb 1;258(1):146-54
12600782
Nature. 1966 Apr 16;210(5033):259-61
4289018
Cell Biochem Biophys. 2006;44(3):446-52
16679532
Biophys J. 1995 Oct;69(4):1447-55
8534815
J Liposome Res. 2007;17(3-4):165-72
18027236
Vaccine. 2005 Jan 11;23(8):975-6
15620469
Nanomedicine (Lond). 2007 Feb;2(1):85-98
17716195
Proc Natl Acad Sci U S A. 1984 Oct;81(19):6159-63
6333027
Biochemistry. 1978 Sep 5;17(18):3759-68
698196
Biochim Biophys Acta. 2007 Jun;1768(6):1518-25
17451640
Anal Chem. 2008 Mar 1;80(5):1806-12
18232711
Vaccine. 2006 Mar 6;24(10):1680-6
16300864
Langmuir. 2004 Oct 26;20(22):9535-40
15491183
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6725-30
11997441
Methods. 2006 Sep;40(1):1-9
16997708
Expert Rev Vaccines. 2003 Apr;2(2):269-83
12899577
Int J Pharm. 2007 Aug 1;340(1-2):216-22
17452086
Vaccine. 2009 Sep 25;27(42):5760-71
19664738
Adv Colloid Interface Sci. 2006 Sep 13;121(1-3):51-75
16769012
Nano Lett. 2005 May;5(5):829-34
15884879
J Am Chem Soc. 2008 Feb 20;130(7):2140-1
18229924
Immunology. 2007 Jun;121(2):216-26
17302734
Trends Biochem Sci. 2008 Jan;33(1):9-19
18165013
Anal Chim Acta. 2007 Apr 18;589(1):76-83
17397656
Biochem Biophys Res Commun. 1978 Apr 28;81(4):1080-6
666808
J Antimicrob Chemother. 2003 Sep;52(3):412-8
12917237
J Am Chem Soc. 2004 Oct 27;126(42):13816-21
15493941
Nat Med. 2002 Jan;8(1):81-4
11786911
J Nanobiotechnology. 2008 May 07;6:6
18462496
Immunol Rev. 2004 Jun;199:191-200
15233735
Colloids Surf B Biointerfaces. 2009 Jul 1;71(2):325-30
19361963
Vaccine. 2002 Jun 21;20(21-22):2743-51
12034101
Immunology. 1966 Oct;11(4):369-86
5924622
Langmuir. 2004 May 11;20(10):3906-12
15969378
Curr Drug Deliv. 2008 Oct;5(4):230-42
18855591
Biochim Biophys Acta. 2000 Nov 23;1508(1-2):146-63
11090823
Biochim Biophys Acta. 1972 Jan 27;260(1):49-58
5062443
Nature. 1982 Mar 11;296(5853):164-5
7063019
Vaccine. 1995 Oct;13(14):1263-76
8585280
Int J Pharm. 2009 Feb 9;367(1-2):187-94
18930127
Lancet Infect Dis. 2004 Feb;4(2):84-90
14871632
FASEB J. 2008 Sep;22(9):3389-402
18556649
Vaccine. 2005 Jul 8;23 Suppl 1:S26-38
16026906
J Colloid Interface Sci. 1997 Sep 1;193(1):104-11
9299094
Curr Drug Deliv. 2005 Oct;2(4):395-400
16305442
Biophys J. 2003 Dec;85(6):3839-47
14645073
Biophys Chem. 2005 Feb 1;113(2):183-92
15617826
Pharm Biotechnol. 1995;6:277-96
7551221
Biophys J. 1985 Jan;47(1):105-13
3978184
Biochim Biophys Acta. 1983 Aug 24;733(1):172-9
6882751
BMC Biotechnol. 2009 Jan 19;9:5
19152701
Vaccine. 2004 Sep 9;22(27-28):3658-68
15315845
J Appl Toxicol. 2002 Sep-Oct;22(5):333-44
12355563
J Antimicrob Chemother. 2006 Jul;58(1):66-75
16636081
Infect Immun. 1997 May;65(5):1710-5
9125551
Adv Drug Deliv Rev. 1998 Jul 6;32(3):155-172
10837642
Int J Pharm. 2008 Dec 8;364(2):272-80
18555624
J Immunol. 1996 Apr 15;156(8):2809-18
8609400
Hum Vaccin. 2006 Jan-Feb;2(1):1-7
17012895
Vaccine. 2002 May 31;20 Suppl 3:S24-33
12184361
J Lipid Res. 1999 Aug;40(8):1495-500
10428986
J Chromatogr A. 2003 Jul 4;1004(1-2):81-90
12929964
Methods. 1999 Sep;19(1):156-62
10525452
Biochim Biophys Acta. 1977 Oct 17;470(2):185-201
911827
Nano Lett. 2005 Feb;5(2):281-5
15794611
Curr Med Chem. 2003 Nov;10(22):2425-46
14529483
J Nanosci Nanotechnol. 2009 Jun;9(6):3578-86
19504885
Biochim Biophys Acta. 2004 May 27;1663(1-2):135-42
15157616
Langmuir. 2005 Oct 25;21(22):10160-4
16229540
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4942-6
8506338
J Antimicrob Chemother. 2005 May;55(5):727-34
15761070
J Immunol. 1974 Apr;112(4):1526-34
4815095
Biochim Biophys Acta. 1976 Sep 7;443(3):313-30
963059
J Colloid Interface Sci. 2007 Sep 15;313(2):519-26
17532328
Langmuir. 2005 Oct 11;21(21):9495-501
16207027
J Colloid Interface Sci. 2006 Jan 1;293(1):240-7
16095603
Int J Pharm. 2005 Jul 25;298(2):315-22
15961266